Compare Fresenius Kabi Onco. with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs VENUS REMEDIES - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. VENUS REMEDIES FRESENIUS KABI ONCO./
VENUS REMEDIES
 
P/E (TTM) x 22.1 -1.0 - View Chart
P/BV x 3.1 0.1 4,300.8% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   VENUS REMEDIES
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
VENUS REMEDIES
Mar-18
FRESENIUS KABI ONCO./
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs176126 139.8%   
Low Rs7961 128.5%   
Sales per share (Unadj.) Rs37.7301.8 12.5%  
Earnings per share (Unadj.) Rs5.1-24.9 -20.5%  
Cash flow per share (Unadj.) Rs6.72.5 264.2%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.5293.3 14.5%  
Shares outstanding (eoy) m158.2312.34 1,282.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 1,089.9%   
Avg P/E ratio x25.0-3.8 -664.6%  
P/CF ratio (eoy) x18.936.7 51.5%  
Price / Book Value ratio x3.00.3 938.2%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1351,154 1,745.1%   
No. of employees `0001.20.9 124.5%   
Total wages/salary Rs m703393 178.9%   
Avg. sales/employee Rs Th5,176.24,026.1 128.6%   
Avg. wages/employee Rs Th610.4425.0 143.6%   
Avg. net profit/employee Rs Th699.6-331.8 -210.8%   
INCOME DATA
Net Sales Rs m5,9633,724 160.1%  
Other income Rs m1823 80.0%   
Total revenues Rs m5,9813,747 159.6%   
Gross profit Rs m1,430395 362.2%  
Depreciation Rs m258338 76.2%   
Interest Rs m-26354 -7.3%   
Profit before tax Rs m1,216-275 -441.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m34232 1,082.9%   
Profit after tax Rs m806-307 -262.6%  
Gross profit margin %24.010.6 226.2%  
Effective tax rate %28.1-11.5 -245.1%   
Net profit margin %13.5-8.2 -164.0%  
BALANCE SHEET DATA
Current assets Rs m5,1022,638 193.4%   
Current liabilities Rs m2,3852,305 103.5%   
Net working cap to sales %45.68.9 509.4%  
Current ratio x2.11.1 186.9%  
Inventory Days Days150135 110.8%  
Debtors Days Days11346 244.5%  
Net fixed assets Rs m5,1484,871 105.7%   
Share capital Rs m158123 128.2%   
"Free" reserves Rs m6,5563,496 187.5%   
Net worth Rs m6,7323,619 186.0%   
Long term debt Rs m9521,374 69.3%   
Total assets Rs m10,3887,509 138.3%  
Interest coverage x-45.80.2 -20,530.1%   
Debt to equity ratio x0.10.4 37.2%  
Sales to assets ratio x0.60.5 115.7%   
Return on assets %7.50.6 1,189.3%  
Return on equity %12.0-8.5 -141.2%  
Return on capital %14.61.6 923.0%  
Exports to sales %74.50-   
Imports to sales %24.813.9 178.6%   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477517 286.0%   
Fx inflow Rs m5,2980-   
Fx outflow Rs m1,772517 343.1%   
Net fx Rs m3,525-517 -682.6%   
CASH FLOW
From Operations Rs m1,274514 247.7%  
From Investments Rs m-1,204-123 978.2%  
From Financial Activity Rs m-196-387 50.7%  
Net Cashflow Rs m-1264 -3,007.1%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.2 166.7%  
FIIs % 9.6 0.6 1,655.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 66.4 13.7%  
Shareholders   42,599 20,121 211.7%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   UNICHEM LAB  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  SHASUN PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Frauds at Public Sector Banks, Upcoming IPOs, and Top Cues in Focus Today(Pre-Open)

India share markets ended their volatile day marginally lower yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 76 points (down 0.2%).

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS